M yocardial infarction and stroke caused by atherosclerosis are the most frequent cardiovascular causes of death and disability in the world despite the progress in prevention and therapy.
M yocardial infarction and stroke caused by atherosclerosis are the most frequent cardiovascular causes of death and disability in the world despite the progress in prevention and therapy. 1 Recent evidence clearly implicates the innate and adaptive immune system in the pathogenesis of atherosclerosis. 2 T lymphocytes, the main orchestrators of adaptive immune responses, have pivotal roles in atherosclerosis. In particular, proinflammatory CD4
+ T lymphocytes such as T helper 1 cells have been shown to promote atherosclerosis in animal models and constitute the predominant T cells in human atherosclerotic plaques. [3] [4] [5] We and others have demonstrated that CD4 + CD28
null T cells, a unique subset of T helper 1 lymphocytes characterized by the lack of costimulatory receptor CD28, are present in high numbers in the circulation and atherosclerotic plaques of patients with acute coronary syndrome (ACS), [6] [7] [8] but these cells are not present in healthy individuals. Moreover, CD4 + CD28
null T cells (from now on abbreviated as CD28 null T cells) produce higher levels of inflammatory cytokines interferon-γ and tumor necrosis factor-α than conventional CD4 + CD28
+ (CD28 + ) T cells. 6, 9 In stark contrast to CD28 + T lymphocytes, CD28 null T cells release cytotoxic molecules (ie, perforin and granzymes) 6 that are instrumental in killing endothelial and vascular smooth muscle cells in vitro. 10 These properties suggest that CD28 null T cells have harmful effects in atherosclerosis, although a direct causal link is yet to be established, because this subset of T cells is present only in humans with an equivalent population absent in mice. Recently, we were the first to show that the distinguishing feature between CD28 null and conventional CD28 + T cells in ACS patients is a significantly higher expression on CD28 null T cells of alternative costimulatory receptors 4-1BB and OX40 6 . We further demonstrated that 4-1BB and OX40 have critical roles in regulating the production of inflammatory cytokines interferon-γ and tumor necrosis factor-α and perforin release from CD28 null T cells in ACS. 6 In addition to their roles in T-cell costimulation, 4-1BB and OX40 are important for the survival of T cells. 11, 12 As mentioned, ACS patients are known to harbor significantly higher numbers of CD28 null T cells in comparison with patients who have stable angina (SA) and healthy subjects. 8, 13 Importantly, Background-The number of CD4 + CD28 null (CD28 null ) T cells, a unique subset of T lymphocytes with proinflammatory and cell-lytic phenotype, increases markedly in patients with acute coronary syndrome (ACS). ACS patients harboring high numbers of CD28 null T cells have increased risk of recurrent severe acute coronary events and unfavorable prognosis. The mechanisms that govern the increase in CD28 null T cells in ACS remain elusive. We investigated whether apoptosis pathways regulating T-cell homeostasis are perturbed in CD28 null T cells in ACS.
Methods and Results-We found that CD28
null T cells in ACS were resistant to apoptosis induction via Fas-ligation or ceramide. This was attributable to a dramatic reduction in proapoptotic molecules Bim, Bax, and Fas in CD28 null T cells, whereas antiapoptotic molecules Bcl-2 and Bcl-xL were similar in CD28 null and CD28 + T cells. We also show that Bim is phosphorylated in CD28 null T cells and degraded by the proteasome. Moreover, we demonstrate for the first time that proteasomal inhibition restores the apoptosis sensitivity of CD28 null T cells in ACS.
Conclusions-We show that CD28
null T cells in ACS harbor marked defects in molecules that regulate T-cell apoptosis, which tips the balance in favor of antiapoptotic signals and endows these cells with resistance to apoptosis. We demonstrate that the inhibition of proteasomal activity allows CD28 null T cells to regain sensitivity to apoptosis. A better understanding of the molecular switches that control the apoptosis sensitivity of CD28 null T cells may reveal novel strategies for targeted elimination of these T cells in ACS patients. thereby allowing Bax to exert its proapoptotic actions.
We hypothesized that the induction of apoptosis, which mediates the elimination of T cells, is dysregulated in CD28 null T cells, and this could explain their accumulation in ACS patients. With this in view, we investigated the sensitivity of CD28 null T cells from ACS patients to apoptosis. We provide novel evidence that, in ACS, CD28 null T cells are resistant to apoptosis. We further demonstrate that the resistance to apoptosis is attributable to the preponderance of antiapoptotic signals in CD28
null T cells as a result of a marked reduction in proapoptotic molecules Bim and Bax and the death receptor Fas. Critically, we propose a novel mechanism that links Bim phosphorylation and its subsequent degradation by the proteasome as a key event that governs the loss of apoptosis sensitivity in CD28 null T cells in ACS patients. Our data suggest, for the first time, that proteasome inhibition restores apoptosis sensitivity in CD28 null T cells, which could potentially open new therapeutic avenues to eliminate these cells.
Methods

Patient Population
Peripheral blood was obtained from patients with a diagnosis of ACS (ST-elevation myocardial infarction and non-ST-elevation myocardial infarction) and patients with SA. The number of patients used in individual experiments is specified in the figure legends. Blood samples were collected 4 to 12 hours from the onset of chest pain. The demographic details and clinical characteristics of patients used to compare the levels of apoptotic molecules in CD28 null T cells from ACS and SA patients are provided in Table I in the online-only Data Supplement. Patients with evidence of infectious diseases, malignancies, hematologic or immunologic disorders, treatment with antiinflammatory drugs other than aspirin, and an ejection fraction <40 were excluded. The study was approved by the local research ethics committee; informed consent was obtained from all study subjects.
Flow Cytometric Analysis
The following antibodies were used: CD4-FITC, CD28-APC, Bcl-2-PE (all from BD Biosciences), Fas/CD95-PE, FasL(CD95L)-PE (eBiosciences), and Bcl-xL-PE (Abcam). Purified Bim (BD Biosciences) and purified Bax (R&D Systems) were used followed by labeling with donkey anti-rabbit-PE (eBiosciences). Surface and intracellular staining were performed in accordance with the manufacturer's instructions. In brief, 100 μL of blood was incubated with antibodies for 30 to 40 minutes; red blood cells were lysed by using Lyse/Fix buffer (BD Biosciences). For intracellular staining, cells were fixed and permeabilized by using the Cytofix/Cytoperm buffer (BD Biosciences) before the addition of antibodies for Bcl-2, Bcl-xL, Bim, and Bax. Samples were acquired on a FACSCalibur (BD Biosciences), and data were analyzed by using the FlowJo software. Mean fluorescence intensity was calculated by subtracting the mean fluorescence intensity of samples stained with isotype control antibodies from the mean fluorescence intensity of samples stained with specific antibodies.
Cell Isolation
Histopaque (Sigma) was used to isolate peripheral blood mononuclear cells. CD4 + T cells were sorted by negative selection by using the CD4 + T-cell isolation kit II (Miltenyi Biotech) as per the manufacturer's instructions. The purity of sorted CD4 + T cells was 90% to 95%. CD28 null and CD28 + T cells were sorted from the purified CD4 + T cells by using the CD28 Microbead kit II (Miltenyi Biotech) as per the manufacturer's instructions. The purity of sorted CD28 null and CD28 + T cells ranged from 85% to 95% ( Figure I in the online-only Data Supplement).
T-Cell Activation and Proliferation Assays
Peripheral blood mononuclear cells were cultured at 5×10 5 cells per well in 96-well U-bottomed plates (Nunc) in the presence or absence of 2 μg/mL plate-bound anti-CD3 antibodies (eBioscience) for 4 days before the detection of apoptotic molecules as described for whole-blood samples. Cells were cultured in Roswell Park Memorial Institute 1% penicillin/streptomycin/l-glutamine (all from Gibco) supplemented with 5% pooled human AB serum (Lonza) and 25 IU/ mL interleukin-2 (Roche). To assess the proliferation of CD28 null and CD28 + T cells from ACS patients, T cells were labeled with 1 μmol/L carboxyfluorescein succinimidyl ester and stimulated with 2 μg/mL plate-bound anti-CD3 antibodies (eBioscience), as previously described. 20 Cells were cultured in Roswell Park Memorial Institute 1% penicillin/streptomycin/l-glutamine (all from Gibco) supplemented with 5% pooled human AB serum (Lonza) and 25 IU/mL interleukin-2 (Roche) for 4 days. Proliferation, as visualized by carboxyfluorescein succinimidyl ester dilution, was quantified by flow cytometry.
Millipore) followed by activation with anti-CD3 antibodies in the continuous presence of the inhibitor. Cells were fixed with BD Cytofix Fixation buffer for 10 minutes at 37°C and then permeabilized with BD PhosFlow Perm buffer III for 30 minutes on ice before staining with phospho site-specific antibodies, as per the manufacturer's recommendations.
Apoptosis Assays
Sorted CD28 null and CD28 pos T cells were cultured at 5×10 4 cells per well in 96-well U-bottomed plates (Nunc) in serum-free X-Vivo medium (Lonza) supplemented with 1% penicillin/streptomycin/lglutamine and 25 IU/mL interleukin-2. For apoptosis induction, cells were treated with 100 ng/mL of anti-Fas clone CH11 antibody (Millipore) or 50 μmol/L C2-ceramide (Enzo Life Sciences). Apoptotic cells were measured at 20 hours by the use of annexin V-fluorescein isothiocyanate and 7-aminoactinomycin D (7-AAD; BD Biosciences) according to the manufacturer's instructions. In some experiments, cells were treated with 5 μg/mL, 10 μg/mL, 30 μg/mL, and 90 μg/mL atorvastatin Pfizer (Selleckchem) or rosuvastatin (Selleckchem) and cultured for 48 hours before apoptosis detection. Statins were purchased as reconstituted pure active compound. Where indicated, cells were pretreated with the ERK1/2-specific inhibitor PD184352 (5 μmol/L, Sigma) or the proteasomal inhibitor MG-132 (10 nmol/L, Merck Millipore) before CH11 treatment. The induction of apoptosis as a percentage was calculated as follows: 100×(percent apoptotic cells with CH11 -percent apoptotic cells without CH11)/(percent apoptotic cells without CH11). Where indicated, the normalization of apoptosis was performed to pool data from different patients. The percentage of CD28 pos apoptotic cells in samples treated with CH11 alone was normalized to 100. All other samples were normalized accordingly.
Statistical Analysis
Categorical data were analyzed by the χ 2 test. Statistically significant differences were determined by using the Student t test, analysis of variance with post test multiple comparisons, or Wilcoxon matchedpairs signed rank test (as indicated in the figure legends). Probability values of <0.05 were considered statistically significant. Statistical analysis was performed by using the GraphPad Prism software version 5.02 and 6.04.
Results
CD28 null T Cells From ACS Patients Are Resistant to Apoptosis
Two features led us to hypothesize that CD28 null T cells in ACS patients have alterations in apoptosis sensitivity: (1) their number is increased 8 and (2) these cells express higher levels of alternative costimulatory receptors 4-1BB and OX40 6 , which have been shown to promote the survival of other subsets of T lymphocytes. 11, 12 To verify this hypothesis, we examined the response of CD28 null T cells to apoptosis induction. For this purpose, we treated purified CD28 null and CD28 + T cells with CH11, a widely used agonistic anti-Fas antibody that triggers apoptosis in T cells by mimicking the effect of Fas ligation by FasL. 21, 22 Apoptosis induction was quantified by using Annexin-V (AxV) and 7 T cells were treated with C2-ceramide, a membrane-permeable ceramide analogue that has been suggested to induce apoptosis via the mitochondrial pathway through the release of cytochrome c from the mitochondria. 23 As observed with CH11, C2-ceramide treatment resulted in a good induction of early and late apoptosis in CD28 + T cells (Figure 2A and 2B). In keeping with our results with CH11, CD28 null T cells from ACS patients underwent significantly less apoptosis in response to C2-ceramide in comparison with CD28 + T cells (n=10, P<0.005 for early apoptosis and P<0.05 for late apoptosis; Figure 2A through 2C).
It has been suggested that statins could induce apoptosis of CD28 null T cells. 24 To test this, we cultured purified CD28 null and CD28 + T cells either alone or in the presence of increasing concentrations of atorvastatin or rosuvastatin for 48 hours and quantified apoptosis induction. At all concentrations tested (5, 10, 30, and 90 μg/mL), atorvastatin and rosuvastatin did not induce significant apoptosis in either CD28 null or CD28 + T cells ( Figure IIA and IIB in the online-only Data Supplement). It is noteworthy that the concentration of statins used in these experiments corresponded to plasma concentrations reached in patients receiving treatment with statins. 25 Furthermore, the highest concentration tested was well above the maximum recommended dose of 80 mg atorvastatin or 40 mg rosuvastatin.
These results demonstrate that statins do not induce apoptosis in CD28 null T cells. Another reason for an increase in the number of CD28 null T cells in ACS patients may be the differences in the proliferation of CD28 null and CD28 + T cells. Therefore, we quantified the proliferation of sorted CD28 null and CD28 + T cells following stimulation with plate-bound anti-CD3 cross-linking antibodies by using the carboxyfluorescein succinimidyl ester-dilution method. As seen in Figure III in the online-only Data Supplement, CD28 + T cells proliferated efficiently in response to anti-CD3 antibodies. Indeed, >80% of CD28 + T cells exhibited carboxyfluorescein succinimidyl ester dilution and had undergone 1 to 5 division rounds. In contrast, CD28 null T cells had a slower division rate and proliferated significantly less than CD28 + T cells.
CD28 null T Cells From ACS Patients Express Low Levels of Death Receptor Fas and Proapoptotic Molecules Bim and Bax
Following on our findings that CD28 null T cells in ACS are resistant to apoptosis, we further investigated the mechanisms underlying the apoptosis resistance of this cell subset. Whether cells undergo apoptosis or survive depends on the balance between pro-and antiapoptotic signals. We therefore examined the expression of death receptor Fas and its ligand FasL, and proapoptotic (Bim and Bax) and antiapoptotic (Bcl-2, Bcl-xL) molecules, as well, in circulating CD28 null T cells from ACS patients (n=25). We analyzed CD28 null T cells directly ex vivo by staining fresh blood samples with monoclonal antibodies. We found that CD28 null T cells have significantly reduced levels of Fas in comparison with 
conventional CD28
+ T cells, whereas there was no difference in FasL expression (P<0.001 for Fas; Figure 3A and 3B). In addition, levels of proapoptotic proteins Bim and Bax were significantly decreased in CD28 null T cells in comparison with CD28 + T cells (P<0.001; Figure 3A and 3B). In contrast, the antiapoptotic molecules Bcl-2 and Bcl-xL were expressed at similar levels in CD28
null T cells and their conventional CD28 + counterparts ( Figure 3A and 3B). These results demonstrate that the balance between pro-and antiapoptotic molecules is altered in favor of antiapoptotic signals in CD28 null T cells in ACS.
CD28 null T Cells Fail to Upregulate Proapoptotic Molecules Bim and Bax on Activation
Activation of T cells is known to sensitize them to apoptosis. 14, 26 We therefore investigated the impact of T-cell activation on the expression of Fas, Bim, and Bax proapoptotic molecules in CD28 null T cells from ACS patients. For this purpose, cells were cultured in vitro for 4 days in the presence or absence of signals that activate T cells (ie, anti-CD3 crosslinking antibodies). We showed that unstimulated CD28 null T cells from ACS patients maintained low levels of Fas, Bim, and Bax following 4 days of culture ( Figure 
Bim and Bax Are Markedly Lower on CD28 null T Cells in ACS Than in SA
In comparison with healthy individuals, the number of circulating CD28 null T cells increases not only in ACS patients, but also in SA patients, albeit at lower levels than in ACS. 13 We therefore investigated whether the alterations in apoptotic molecules that we identified in ACS were also present in CD28 null T cells from patients with SA. There was no significant difference in the demographic and clinical characteristics of the 2 patient groups ( Figure 4A ) and that the antiapoptotic molecule Bcl-2 was higher in CD28 null T cells from ACS patients (P<0.05; Figure 4B ). No differences were detected in the expression of Fas, FasL, and antiapoptotic molecule Bcl-xL in CD28 null T cells between ACS and SA patients ( Figure 4A and 4B). Our findings suggest that the reduction in Bim and Bax is more pronounced in CD28 null T cells in ACS patients in comparison with SA and that this is accompanied by higher levels of the antiapoptotic protein Bcl-2.
ERK1/2 Is Activated in CD28 null T Cells From ACS Patients
Because the proapoptotic molecule Bim has a pivotal role in regulating apoptosis, we next examined the mechanisms that underlie the reduction in Bim levels in CD28 null T cells in ACS. It has been suggested that posttranslational modifications of Bim, such as phosphorylation, target it for proteasomal degradation, 27 thereby promoting cell survival. Activation of the ERK1/2 signaling pathway has been shown to promote Bim phosphorylation and proteasome-dependent degradation of phosphorylated Bim. 28 We therefore analyzed ERK1/2 signaling in CD28 null and CD28 + T cells from ACS patients. We used the PhosFlow technique, which, in comparison with standard Western blotting, provides a direct cell-based assessment of signaling events when the number of cells obtainable for analysis is low, as is the case with CD28 null T cells. Purified CD28 null and CD28 + T cells were analyzed either directly (resting T cells) or following activation by cross-linking CD3 with monoclonal antibodies. We observed consistently high-baseline ERK1/2 phosphorylation in resting CD28 null T cells ( Figure 5A and 5C). In contrast, resting CD28 + T cells exhibited low levels of ERK1/2 phosphorylation, which were significantly lower than those observed in resting CD28 null T cells (P<0.001; Figure 5A and 5C). These results clearly demonstrate constitutive activation of ERK1/2 in resting CD28 null T cells in ACS. In vitro stimulation with anti-CD3 antibodies led to the upregulation of phosphorylated ERK1/2 in both CD28 null and CD28 + T cells ( Figure 5B and 5C ). Of note, even following activation, the levels of phosphorylated ERK1/2 remained significantly higher in CD28 null T cells than in their conventional CD28 + counterparts (P<0.001; Figure 5A and 5C).
Bim Is Phosphorylated in CD28 null T Cells From ACS Patients
As mentioned, ERK1/2 activation has been shown to induce the phosphorylation of Bim, which targets Bim for degradation via the proteasome. 28 We therefore assessed the expression of phosphorylated Bim (phospho-Bim) in CD28 null T cells in ACS patients by using an antibody that recognizes solely the phosphorylated form of human Bim. Phospho-Bim was detected in both resting CD28 null and CD28 + T cells ( Figure 6A  and 6C ). However, resting CD28 null T cells expressed significantly higher levels of phospho-Bim than conventional CD28 + T cells (P<0.001; Figure 6A and 6C). Following activation with anti-CD3 cross-linking antibodies, phospho-Bim increased further in CD28 null T cells, whereas in CD28 + T cells it remained unchanged ( Figure 6B and 6C) . These results support our hypothesis that Bim is phosphorylated in CD28 null T cells, which may tag it for proteasomal degradation. To determine whether ERK activation plays a role in Bim phosphorylation in CD28
null T cells, we preincubated purified CD28 null and CD28 + T cells from ACS patients with PD184352, a specific ERK1/2 inhibitor 29 followed by activation with anti-CD3 cross-linking antibodies in the continuous presence of the inhibitor and quantified phospho-Bim expression. As shown previously ( Figure 6B ), activation of CD28 null T cells increased phospho-Bim levels ( Figure 6E ). This increase was abrogated by ERK1/2 inhibition with PD184352 (P<0.05; Figure 6D and 6E). ERK1/2 inhibition did not affect phospho-Bim levels in CD28 + T cells ( Figure 6D and 6E). Bim phosphorylation has been shown to tag the protein for degradation by the proteasome. 28 We therefore examined whether proteasome inhibition affects the levels of phospho-Bim in CD28 null T cells. Treatment with the cell-permeable proteasomal inhibitor Figure 6E ), although it did not have an effect on CD28 + T cells.
Proteasomal Inhibition Restores Apoptosis Sensitivity of CD28 null T Cells in ACS.
We have demonstrated that CD28 null T cells have higher levels of activated ERK1/2, and this associates with Bim phosphorylation and proteasomal degradation in CD28 null T cells. It has been shown that proteasomal degradation of phosphorylated Bim confers apoptosis resistance by leaving Bcl-2 and Bcl-xL unhampered to exert their antiapoptotic effects. 27 We therefore hypothesized that inhibiting Bim phosphorylation by blocking ERK1/2 or preventing phospho-Bim degradation by blocking the proteasome should restore the apoptosis sensitivity of CD28 null T cells. To test this hypothesis we investigated the effect of the ERK1/2 inhibitor PD184352 on apoptosis sensitivity of CD28 null T cells in ACS patients. Purified CD28 null and CD28 + T cells were induced to enter apoptosis by treatment with CH11 in the presence or absence of PD184352. We found that ERK1/2 inhibition with PD184352 did not significantly affect the apoptosis of CD28 null T cells in response to CH11 (Figure 7 ). Even though we observed a trend toward an increase in the percentage of early apoptotic CD28 null T cells, this did not reach statistical significance ( Figure 7) . Next, we investigated the effect of proteasome inhibition on CD28 null T-cell apoptosis. For this, cells were treated with CH11 in the presence or absence of the cell-permeable proteasomal inhibitor MG-132. MG-132 on its own did not affect the viability of CD28 null and CD28 + T cells that were not treated with CH11 ( Figure 8A and 8B) . Importantly, MG-132 significantly increased apoptosis of CD28 null T cells treated with CH11 (P<0.01; Figure 8A and 8B). This was true for both early and late apoptotic CD28 null T cells. Of note, MG-132 did not influence the apoptosis of CD28 + T cells treated with CH11 ( Figure 8A and 8B), suggesting that it did not affect the viability of conventional CD28 + T cells.
Discussion
Here, we report that CD28 null T cells from ACS patients harbor important alterations in apoptosis that could explain their accumulation. We demonstrate for the first time that, in null T cells are endowed with resistance to apoptosis induction both via the death receptor (Fasmediated) and mitochondrial (ceramide-mediated) pathways. Moreover, we show that the molecular basis for the loss of apoptosis sensitivity in CD28 null T cells is a marked reduction in proapoptotic molecules Bim and Bax and death receptor Fas. Critically, we propose a novel mechanism that links Bim phosphorylation and its degradation by the proteasome as the key event that governs the loss of apoptosis sensitivity in CD28 null T cells. In addition, we present promising new results that demonstrate for the first time that apoptosis sensitivity of CD28 null T cells can be reinstated by proteasomal inhibition.
T-cell sensitivity to apoptosis is tightly regulated and the intricate mechanisms controlling this process have not been completely deciphered. Here, we show for the first time that CD28 null T cells from ACS patients are resistant to apoptosis induction and that they exhibit reduced levels of proapoptotic molecules Bim and Bax and death receptor Fas in comparison with conventional CD28 + T cells. Changes in the levels of members of the Bcl-2 family and their interactions have long been recognized to regulate the survival of T cells. 16 In particular, Bim has pivotal roles in controlling the fine balance between proapoptosis and prosurvival molecules in various cells, including T cells. 30 However, the role of Bim in CD28
null T cells has not been previously investigated. Bim 
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acts as an initiator of apoptosis, and, although it does not trigger apoptosis itself, it enables Bax to induce cell death. 30 In viable cells, the proapoptotic function of Bax is inhibited by binding to antiapoptotic molecules (Bcl-2 and Bcl-xL). 31 In response to death signals, Bim translocates from the cytosol/ cytoskeleton to the mitochondria and binds to Bcl-2, displacing it from its complex with Bax, which in turn releases Bax to trigger apoptosis. Thus, Bim is crucial for the proapoptotic action of Bax. 30 Our finding that CD28 null T cells in ACS have significantly reduced levels of both Bim and Bax suggests that, in these cells, the antiapoptotic activity of Bcl-2/ Bcl-xL is left unopposed by proapoptotic signals from Bim and Bax, which may endow CD28 null T cells with apoptosis resistance and give these cells a survival advantage. This is supported by other studies which report that the induction of either Bim or Bax counteracts Bcl-2 antiapoptotic signals and can enable apoptosis even when Bcl-2 levels are maintained. 30 Furthermore, the deletion of Bim and Bax inhibited the death of murine T cells in knockout models. 32, 33 Bim has also been suggested to collaborate with Fas in the control of T-cell homeostasis and the elimination of unwanted T cells. 34, 35 Mice deficient in both Bim and Fas accumulate more T cells and display severe autoimmunity in comparison with those deficient in either Bim or Fas that develop mild autoimmune phenomena. 36 Of note, we found that freshly analyzed CD28 null T cells from ACS patients had low levels of both Bim and Fas, which may suggest a pronounced defect in apoptosis sensitivity in these cells. Moreover, the levels of Bim, Bax, and Fas stayed low even when CD28 null T cells were cultured in vitro. Interestingly, following in vitro activation, which is known to increase the sensitivity of T cells to apoptosis, Fas increased on CD28 null T cells to levels that are comparable to CD28 + T cells, whereas Bim and Bax remained significantly low. These findings suggest that Bim and Bax are the major drivers of apoptosis resistance in CD28 null T cells. Our results show that antiapoptotic molecules Bcl-2 and Bcl-xL are expressed at similar levels in CD28 null and CD28 + T cells in ACS patients, implying that these molecules do not have a central role in apoptosis resistance of CD28 null T cells. Our findings are in contrast to data on CD28 null T-cell clones from patients with rheumatoid arthritis, 37, 38 another disease in which this subset expands. These studies reported an increase in Bcl-2 in CD28 null T-cell lines and clones in comparison with lines and clones derived from CD28 + T cells. In addition, they did not identify any differences in Fas, Bcl-xL, and Bax between CD28 null and CD28 + T cell lines, whereas Bim was not investigated. The Bcl-2 upregulation reported in these studies on patients with rheumatoid arthritis could be explained by the use of CD28 null T-cell lines/clones, instead of analyzing fresh primary T cells (as was done in our study on ACS patients). Clonal expansion alters the levels of pro-and antiapoptotic molecules, because cells are subjected to several rounds of activation in vitro, aimed at extending their life in culture, and therefore may not be representative of the apoptosis sensitivity of these cells in vivo.
It has been suggested that rosuvastatin may induce apoptosis of CD28 null T cells in ACS patients. 37 In our hands, direct treatment of pure populations of CD28 null and CD28 + T cells from ACS patients with increasing doses of atorvastatin or rosuvastatin did not induce apoptosis. Indeed, many ACS patients who are already on statin therapy still exhibit high numbers of CD28 null T cells and previous reports showed that CD28 null T cell frequency remained unchanged for up to 2 years after an acute coronary event, although statins are routinely prescribed following ACS, 13 which indicates that statins do not induce apoptosis in CD28 null T cells, in line with our in vitro findings. Given Bim's central role in controlling the balance between pro-and antiapoptotic signals, we investigated the mechanisms responsible for Bim reduction in CD28 null T cells. Previous studies on cancer cell lines, fibroblasts, and CD8 + T cells from OT-I transgenic mice have suggested that Bim can be degraded by the proteasome, following posttranscriptional modifications such as phosphorylation. 27, 39 We demonstrate that ERK1/2, a protein kinase that has been implicated in regulating Bim levels by phosphorylating it, is constitutively activated (phosphorylated) in resting CD28 null T cells from ACS patients, whereas conventional CD28 + T cells exhibited significantly lower ERK1/2 activation. In addition, we also detected higher levels of phosphorylated ERK1/2 following the activation of CD28 null T cells, well above those present in CD28 + T cells. Another novel finding was that CD28 null T cells express significantly higher levels of phosphorylated Bim than conventional CD28 + counterparts. In support of a role for ERK1/2 in Bim phosphorylation, we present data showing that ERK1/2 inhibition reduced phosphorylated Bim levels in CD28 null T cells following activation via CD3 crosslinking. Bim phosphorylation has been shown to tag this protein for degradation by the proteasome, which may explain the marked reduction in Bim that characterizes CD28 null T cells in ACS patients. In support of this, we demonstrated that proteasome inhibition increased phosphorylated Bim levels in both resting and activated CD28 null T cells, confirming a central role for the proteasome in Bim regulation.
Next, we sought a method to restore the apoptosis sensitivity of CD28 null T cells while sparing the conventional T cells. We tested 2 strategies: (1) ERK1/2 inhibition to prevent Bim phosphorylation, and (2) proteasome inhibition to prevent phospho-Bim degradation. We demonstrated that treatment with the proteasomal inhibitor MG-132 restored apoptosis sensitivity of CD28 null T cells to CH11 in ACS patients. Encouragingly, proteasomal inhibition did not alter apoptosis of conventional T cells. Proteasomal inhibitors have been used to sensitize cancer cells to apoptosis. Of note, the dose of proteasomal inhibitor that restored apoptosis sensitivity in CD28 null T cells was in the nanomolar range, ≈1000 times lower than the doses used to induce apoptosis in cancer cells, suggesting that the resensitization of CD28 null T cells to apoptosis could potentially be achieved in vivo in ACS at much lower doses of proteasomal inhibitors than those used for the elimination of malignant cells, with a lower side-effect profile. This makes the proteasome an attractive target for selective elimination of CD28 null T cells, while sparing their conventional counterparts and preventing bystander immunosuppression.
In our hands, ERK inhibition failed to significantly alter apoptosis sensitivity of CD28 null T cells from ACS patients. This suggests that proteasomal degradation of Bim in CD28 null T cells is not solely controlled by ERK1/2, as is the case for other cells such as CD8 + T cells from OT-I transgenic mice. Indeed, we found that ERK1/2 inhibition failed to affect the levels of phospho-Bim in resting CD28 null T cells, in which we showed that ERK is constitutively activated. Interestingly, ERK inhibition abrogated de novo induced Bim phosphorylation on activation of CD28 null T cells. In contrast, proteasomal inhibition increased phospho-Bim levels in both resting and activated CD28
null T cells. This may explain why proteasomal inhibition was more effective at restoring apoptosis sensitivity in CD28
null T cells than ERK1/2 inhibition. Additionally, one cannot exclude that other protein kinases may contribute to Bim phosphorylation in resting CD28 null T cells, which will be explored in future work.
In summary, we show that CD28 null T cells in ACS patients exhibit resistance to apoptosis as a result of a reduction in proapoptotic molecules Bim, Bax, and Fas, and we propose a novel strategy to restore apoptosis sensitivity in CD28 null T cells via proteasome inhibition. Because ACS patients who harbor high numbers of CD28 null T cells have increased risk for recurrent severe acute coronary events and poor prognosis, deciphering the regulation of life and death decisions in CD28 null T cells will be useful not only in understanding the behavior of this unique T-cell subset, but may also have potential therapeutic implications.
CLINICAL PERSPECTIvE
Patients with acute coronary syndrome (ACS) who harbor high numbers of CD4 + CD28
null (CD28 null ) T cells, a subset of proinflammatory lymphocytes, have increased risk for recurrent acute coronary events and unfavorable prognosis. The reasons why these cells accumulate in ACS are not currently understood. T cells that are no longer needed and potentially harmful are eliminated from the immune repertoire by apoptosis. In the present study, we examined apoptosis pathways in CD28 null and conventional CD4 + CD28
+ (CD28 + ) T cells in ACS patients. Apoptosis analysis showed that, in comparison with conventional CD28 + T cells, CD28 null T cells were significantly less sensitive to apoptosis induction either via the death receptor (Fas) or the mitochondrial pathway. Of note, we found marked reduction in proapoptotic mitochondrial molecules Bim and Bax and the death receptor Fas in CD28 null T cells in ACS patients. The reduction in Bim was mediated by extracellular signal-regulated kinase 1/2 through the phosphorylation of Bim, which targeted Bim for degradation by the proteasome. Importantly, we demonstrate that proteasome inhibition restores the apoptosis sensitivity of CD28 null T cells from ACS patients. Our novel data show that CD28 null T cells from ACS patients acquire resistance to apoptosis as a result of defects in molecules that regulate apoptotic cell death. The identification of defects in apoptosis regulation in CD28 null T cells in ACS provides a novel insight into the mechanisms that govern the accumulation of this cell subset in patients and unveils the proteasome as a potential molecular switch for targeted elimination of these harmful cells. 
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SUPPLEMENTAL MATERIAL
